86: Pimavanserin and Atypical Antipsychotics to Treat Parkinson Disease Psychosis

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, we spoke with Dilesh Doshi, PharmD, vice president of Health Economic and Outcomes Research at Acadia Pharmaceuticals. He spoke on the advantages and benefits of pimavanserin (Nuplazid; Acadia), the only FDA-approved therapy to treat Parkinson disease psychosis. Additionally, he discussed recent data that compared efficacy and safety of other off-label therapies such as clozapine and quetiapine.  Looking for more Parkinson disease discussion? Check out the NeurologyLive® movement disorder clinical focus page. Episode Breakdown: 1:10 – Mechanistic differences between pimavanserin and other atypical antipsychotics 3:00 – Understanding drug-to-drug interactions for PDP 5:05 – Decision making with quetiapine and negative cognitive effects 7:10 – Improved use of pimavanserin since approval 9:00 – Neurology News Minute 11:40 – Potential predictors of mortality in Parkinson disease psychosis 15:20 – Possibility of preventing PD psychosis 17:20 – Future research on identifying subgroups of responders to treatment This episode is brought to you by Medical World News, a streaming channel from MJH Life Sciences®. Check out new content and shows every day, only at medicalworldnews.com. The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: Tiziana Announces Planned Phase 2 Study of Foralumab in Progressive Multiple Sclerosis Blarcamesine Deemed Safe, Effective in Phase 2 Extension Study of Parkinson Disease Dementia Eplontersen Continues to Show Clinical Benefit in Long-Term Analysis of hATTR Polyneuropathy Reldesemtiv to be Discontinued in ALS Following Data Monitoring Committee Analysis Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.